

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2022-02-03

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2022

Zinzino group revenue increased with a total of 2 %, compared with the previous year.

The revenue in January for Zinzino's sales markets remained at the same level as last year and amounted to SEK 102.2 (101.7) million. Faun Pharma's external sales increased by 26% and amounted to SEK 6.7 (5.3) million. Overall, the Group increased revenues by 2% to SEK 108.9 (107.0) million compared with the previous year.

Revenues were distributed as follows:

Regions,MSEK	22-jan	21-jan	Change
The Nordics	26.0	30.6	-15%
Central Europe	18.4	18.5	-1%
East Europe	28.6	27.6	4%
South & West Europe	12.3	10.2	21%
The Baltics	6.4	5.7	12%
North America	4.4	3.7	19%
Asia-Pacific	5.7	5.4	6%
Africa	0.4	0.0	
Zinzino	102.2	101.7	0%
Faun Pharma	6.7	5.3	26%
Zinzino Group	108.9	107.0	2%

Countries in regions:

- The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
- Central Europe: Austria, Germany, Switzerland
- East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
- South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom
- The Baltics: Estonia, Latvia, Lithuania
- North America: Canada, USA
- Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
- Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, [zinzino.com](https://www.zinzino.com)

Pictures for publication free of charge:

Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 09:00 the 3rd of January 2022.

Zinzino is a global D2C company from Scandinavia specializing in biomarker-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available in over 100 markets across the world.

Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India, Taiwan and South Africa.